Artificial Metalloprotein Nanoanalogues: In Situ Catalytic Production of Oxygen to Enhance Photoimmunotherapeutic Inhibition of Primary and Abscopal Tumor Growth. Issue 46 (21st October 2020)
- Record Type:
- Journal Article
- Title:
- Artificial Metalloprotein Nanoanalogues: In Situ Catalytic Production of Oxygen to Enhance Photoimmunotherapeutic Inhibition of Primary and Abscopal Tumor Growth. Issue 46 (21st October 2020)
- Main Title:
- Artificial Metalloprotein Nanoanalogues: In Situ Catalytic Production of Oxygen to Enhance Photoimmunotherapeutic Inhibition of Primary and Abscopal Tumor Growth
- Authors:
- Huang, Rongtao
Ding, Zhaoyang
Jiang, Bang‐Ping
Luo, Zilan
Chen, Ting
Guo, Zhengxi
Ji, Shi‐Chen
Liang, Hong
Shen, Xing‐Can - Abstract:
- Abstract: Photoimmunotherapy (PIT) has shown enormous potential in not only eliminating primary tumors, but also inhibiting abscopal tumor growth. However, the efficacy of PIT is greatly limited by tumor hypoxia, which causes the attenuation of phototherapeutic efficacy and is a feature of the immunosuppressive tumor microenvironment (TME). In this study, one type of brand‐new artificial metalloprotein nanoanalogues is developed via reasonable integration of a "phototherapy‐enzymatic" RuO2 and a model antigen, ovalbumin (OVA) for enhanced PIT of cancers, namely, RuO2 ‐hybridized OVA nanoanalogues (RuO2 @OVA NAs). The RuO2 @OVA NAs exhibit remarkable photothermal/photodynamic capabilities under the near‐infrared light irradiation. More importantly, the photoacoustic imaging and immunofluorescence staining confirm that RuO2 @OVA NAs can remarkably alleviate hypoxia via in situ catalysis of hydrogen peroxide overexpressed in the TME to produce oxygen (O2 ). This ushers a prospect of concurrently enhancing photodynamic therapy and reversing the immunosuppressive TME. Also, OVA, as a supplement to the immune stimulation induced by phototherapy, can activate immune responses. Finally, further combination with the cytotoxic T‐lymphocyte‐associated protein 4 checkpoint blockade is reported to effectively eliminate the primary tumor and inhibit distant tumor growth via the abscopal effect of antitumor immune responses, prolonging the survival. Abstract : Through reasonableAbstract: Photoimmunotherapy (PIT) has shown enormous potential in not only eliminating primary tumors, but also inhibiting abscopal tumor growth. However, the efficacy of PIT is greatly limited by tumor hypoxia, which causes the attenuation of phototherapeutic efficacy and is a feature of the immunosuppressive tumor microenvironment (TME). In this study, one type of brand‐new artificial metalloprotein nanoanalogues is developed via reasonable integration of a "phototherapy‐enzymatic" RuO2 and a model antigen, ovalbumin (OVA) for enhanced PIT of cancers, namely, RuO2 ‐hybridized OVA nanoanalogues (RuO2 @OVA NAs). The RuO2 @OVA NAs exhibit remarkable photothermal/photodynamic capabilities under the near‐infrared light irradiation. More importantly, the photoacoustic imaging and immunofluorescence staining confirm that RuO2 @OVA NAs can remarkably alleviate hypoxia via in situ catalysis of hydrogen peroxide overexpressed in the TME to produce oxygen (O2 ). This ushers a prospect of concurrently enhancing photodynamic therapy and reversing the immunosuppressive TME. Also, OVA, as a supplement to the immune stimulation induced by phototherapy, can activate immune responses. Finally, further combination with the cytotoxic T‐lymphocyte‐associated protein 4 checkpoint blockade is reported to effectively eliminate the primary tumor and inhibit distant tumor growth via the abscopal effect of antitumor immune responses, prolonging the survival. Abstract : Through reasonable integration of "phototherapy‐enzymatic" RuO2 and model antigen ovalbumin, one kind of brand‐new artificial metalloprotein nanoanalogues are developed for enhanced photoimmunotherapeutic inhibition of primary and abscopal tumor growth via in situ tumor‐specific catalytic production of oxygen to alleviate tumor hypoxia. … (more)
- Is Part Of:
- Small. Volume 16:Issue 46(2020)
- Journal:
- Small
- Issue:
- Volume 16:Issue 46(2020)
- Issue Display:
- Volume 16, Issue 46 (2020)
- Year:
- 2020
- Volume:
- 16
- Issue:
- 46
- Issue Sort Value:
- 2020-0016-0046-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-10-21
- Subjects:
- in situ catalysis -- metalloprotein nanoanalogues -- photoimmunotherapy -- ruthenium oxides -- tumor hypoxia
Nanotechnology -- Periodicals
Nanoparticles -- Periodicals
Microtechnology -- Periodicals
620.5 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1613-6829 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/smll.202004345 ↗
- Languages:
- English
- ISSNs:
- 1613-6810
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8309.952000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14859.xml